Blocking USP8 triggers RICTOR breakdown and shrinks prostate tumors in preclinical models
A Science Advances study finds that inhibiting USP8 degrades RICTOR, shutting down mTORC2 but not mTORC1, and suppresses prostate tumor growth in vivo.
Summary
Prostate cancer cells often keep a growth-promoting protein called RICTOR switched on. RICTOR drives mTORC2, a signaling complex related to the mTOR pathway that rapamycin targets. Researchers found that a tumor-suppressing protein, SPOP, normally tags RICTOR for destruction. When SPOP is missing or carries cancer-linked mutations, RICTOR builds up and prostate cancer progresses. They also found that USP8, an enzyme that strips off the destruction tags, protects RICTOR. Blocking USP8 with an inhibitor made RICTOR break down, turned down mTORC2 without affecting mTORC1, and suppressed tumors in vivo. This is preclinical work from cells and animal models; the abstract does not give species, model, or sample sizes. No human treatment data are reported. The finding is a mechanism worth watching for a more selective way to reach the mTOR network in cancer.
Detailed Summary
Why this matters: The mTOR pathway sits at the center of aging biology and cancer. Most drugs that target it, such as rapamycin, act mainly on mTORC1, and long-term inhibition can also affect mTORC2. A way to dial down mTORC2 selectively could open a more precise route to treating tumors driven by this arm of the pathway.
What was studied: Researchers at Beth Israel Deaconess Medical Center, Harvard, and collaborators asked how RICTOR, the key component that controls mTORC2 activity, becomes abnormally active in human prostate cancer. They examined how cells control RICTOR protein levels through ubiquitin-based degradation.
Key results: RICTOR is a substrate of SPOP, a Cullin 3-based ubiquitin ligase adaptor and known prostate cancer tumor suppressor. When SPOP is deficient, or carries cancer-derived mutations, RICTOR is no longer degraded, and prostate cancer progression is promoted. The team then identified USP8 as the upstream deubiquitinase that opposes this process. Inhibiting USP8 specifically suppressed RICTOR/mTORC2 activity without affecting mTORC1. A USP8 inhibitor induced RICTOR degradation alongside marked tumor suppression in vivo.
Implications: The work defines an SPOP-USP8-RICTOR circuit underlying prostate tumorigenesis and offers a rationale for targeting RICTOR indirectly through USP8 inhibition. Because SPOP mutations are common in prostate cancer, tumors carrying them may be especially dependent on this circuit, though the abstract does not test that directly.
Caveats: This is a mechanistic and preclinical finding. The abstract does not state the models, sample sizes, dosing, or toxicity. Nothing is shown about lifespan, function, or outcomes in people. Because USP8 has other substrates, off-target effects and safety remain open questions. Human trials would be needed before any clinical conclusion. This summary rests on the abstract alone.
Key Findings
- Mechanism: RICTOR is a substrate of the SPOP ubiquitin ligase adaptor, which normally targets it for degradation.
- SPOP deficiency or cancer-derived SPOP mutations block RICTOR degradation and promote prostate cancer progression.
- USP8 is the upstream deubiquitinase that stabilizes RICTOR in this circuit.
- USP8 inhibition suppressed RICTOR/mTORC2 activity without affecting mTORC1.
- A USP8 inhibitor induced RICTOR degradation with marked tumor suppression in vivo; no human data reported.
Methodology
Based on the abstract only, the work combines biochemical identification of RICTOR as an SPOP substrate and USP8 as its deubiquitinase with tests of SPOP deficiency and mutations. A USP8 inhibitor was tested in vivo. The abstract does not specify models, sample sizes, or statistics.
Study Limitations
This summary is based on the abstract only, so model details, effect sizes, dosing, and safety data were not available. The results are preclinical, with no human efficacy or toxicity data, and no lifespan or functional outcomes. USP8 regulates other proteins, so specificity and tolerability remain to be shown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
